Soaring demand for obesity drugs was in the spotlight at the world's largest trade show for the pharmaceutical services industry this week, as it fuels a boom for firms that fill and assemble the self-injection pens. A surge in sales of Novo Nordisk's drug Wegovy, which launched in the United States in mid-2021, has propelled the Danish drugmaker to become Europe's most valuable company. U.S. rival Eli Lilly has become the world's most valuable healthcare firm this year as demand for its diabetes drug Mounjaro surges ahead of approval for its use as a weight-loss treatment in the United States, expected by the end of this year.
Jefferies looks forward to welcoming delegates back to its 2023 London Healthcare Conference, taking place in-person from Tuesday, November 14 to Thursday, November 16.
As in previous years, the.
Jefferies Financial Group Inc : Jefferies to Host 14th Annual Global Healthcare Conference in London finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
ADVANZ Pharma Corp. Limited - Update on Formal Sale Process
PR Newswire
London, January 21
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION
THIS ANNOUNCEMENT IS NOT AN ANNOUNCEMENT OF A FIRM INTENTION TO MAKE AN OFFER UNDER RULE 2.7 OF THE CITY CODE ON TAKEOVERS AND MERGERS AND THERE CAN BE NO CERTAINTY THAT AN OFFER WILL BE MADE, NOR AS TO THE TERMS ON WHICH ANY OFFER WILL BE MADE
21 January 2021
Update on Formal Sale Process
AstraZeneca-Alexion merger set to spark wave of pharma deals
Analysts expect more big pharmaceutical firms will seek to buy smaller specialist players to fill their drug pipelines
15 December 2020 • 6:00am
AstraZeneca’s $39bn (£31bn) bid for US rare disease specialist Alexion has fired the starting gun on what could be a wave of deal-making in the pharmaceutical sector next year.
Analysts and investors predict 2021 will see a rebound in deals, stock market flotations and partnerships as investors look for the sort of long-term, stable returns that the pharmaceutical sector can offer; with big pharma looks to beef up its pipelines while borrowing remains cheap.